Warning letter · FDA Warning Letters

Naturista Store LLC: FDA Warning Letter 701480 (Mar 26, 2025)

Agency action: Mar 26, 2025Record ID: fda_warning_-6bdb6aab6301e298
View official source ↗

What happened

Original notice title

Naturista Store LLC MARCS-CMS 701480, March 26, 2025

From the archived source record

As described below, this product is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, your “ADVANCE KING” product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352, and introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a). FDA confirmed through laboratory analysis that a sample of your “ADVANCE KING” product contains the undeclared active pharmaceutical ingredients dexamethasone, diclofenac, and methocarbamol. In addition, the undeclared dexamethasone in “ADVANCE KING” may cause serious side effects when combined with other medications. NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. Diclofenac may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products. Unapproved New Drug Your “ADVANCE KING” product is a drug as defined by section 201(g)(1) of the FD&C Act 21, U.S.C. 321(g)(1) because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body. Misbranded Drug Your “ADVANCE KING” product is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that, in determining whether an article’s labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for your “ADVANCE KING” product does not declare that the product co

What the official notice says to do

Check the original notice for the instructions that apply to the named product, company, and affected lots.

Read the official notice →

Status and source details

Status recorded in the archive
No closeout listed in FDA table
Source checked
Jul 16, 2026
Record revision
16475c3bdcbd

This is a dated record. Its current status may have changed since the source was captured. A record applies to its stated scope; it is not a safety rating for every product from a company.

Sources, dates, and coverage →

What is affected

Product
ADVANCE KING; Hierbas medicinales para CALMAR el DOLOR; Kukamonga Acido Hialuronico
Company
Naturista Store LLC
Lot / identifier
The source does not specify this field.
Market / distribution
The source does not specify this field.